5-FU (5-Fluorouracil)
别名: Fluorouracil, NSC 19893
中文名称:氟尿嘧啶
目录号:S1209 Purity: 99.98%
5-FU (5-Fluorouracil)是DNA/RNA合成抑制剂,在肿瘤细胞中通过抑制胸苷酸合成酶(TS)而干扰核苷酸合成。Fluorouracil 可诱导细胞凋亡并可用于治疗HIV。
CAS: 51-21-8
客户使用Selleck的5-FU (5-Fluorouracil)发表文献258篇
- Nature, 2024 635(8037):201-209
- Mol Cancer, 2024 23(1):186
- Cancer Discov, 2024 10.1158/2159-8290.CD-24-0887
- Nat Cell Biol, 2024 10.1038/s41556-024-01473-0
- Nat Med, 2023 29(3):605-614
- Cell Discov, 2023 9(1):74
- Cancer Discov, 2023 13(10):2192-2211
- Drug Resist Updat, 2023 71:101005
- Cancer Cell, 2022 40(9):957-972.e10
- Cell Res, 2022 10.1038/s41422-022-00731-w
- Cell, 2021 184(25):6119-6137.e26
- Cancer Cell, 2020 37(3):371-386
- J Hematol Oncol, 2020 1;13(1):40
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Gastroenterology, 2019 156(3):708-721
- Cell Stem Cell, 2019 10.1016/j.stem.2019.10.010
- Cell, 2017 170(3):548-563
- J Hematol Oncol, 2017
- Mol Cancer, 2013 12(1):42
- Mol Cell, 2024 S1097-2765(24)00285-5
- Cell Rep Med, 2024 5(7):101627
- Redox Biol, 2024 75:103292
- Redox Biol, 2024 73:103169
- J Adv Res, 2024 S2090-1232(24)00413-2
- Cell Death Dis, 2024 15(8):603
- Cell Death Dis, 2024 15(7):480
- Cell Death Dis, 2024 15(3):187
- Cell Rep, 2024 43(4):114044
- NPJ Precis Oncol, 2024 8(1):52
- J Transl Med, 2024 22(1):1130
- Cell Death Discov, 2024 10(1):422
- Cell Death Discov, 2024 10(1):228
- Lab Chip, 2024 24(23):5251-5263
- iScience, 2024 27(3):109247
- Int J Mol Sci, 2024 25(16)8590
- Int J Mol Sci, 2024 25(4)2167
- Am J Cancer Res, 2024 14(1):378-389
- Neoplasia, 2024 51:100984
- Sci Rep, 2024 14(1):22619
- BMC Cancer, 2024 24(1):357
- Curr Issues Mol Biol, 2024 46(5):3906-3918
- Curr Cancer Drug Targets, 2024 24(10):1071-1079
- Oncol Lett, 2024 28(1):296
- bioRxiv, 2024 2024.05.24.595756
- STAR Protoc, 2024 5(2):103090
- J Clin Invest, 2023 133(3)e158705
- Adv Sci (Weinh), 2023 10(24):e2207322
- Nucleic Acids Res, 2023 gkad001
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101277
- Int J Biol Sci, 2023 19(11):3526-3543
- Cell Rep, 2023 42(4):112324
- Aging Cell, 2023 e13913.
- Biomed Pharmacother, 2023 162:114679
- Cell Death Discov, 2023 9(1):351
- Chin Med J (Engl), 2023 10.1097/CM9.0000000000002816
- iScience, 2023 26(9):107734
- Int J Mol Sci, 2023 24(14)11585
- Front Pharmacol, 2023 14:1142127
- Int J Mol Sci, 2023 24(4)3954
- Cancer Biol Med, 2023 20(4):297-316
- iScience, 2023 26(7):107116
- J Virol, 2023 97(9):e0100523
- J Cell Mol Med, 2023 27(5):659-671
- Cancers (Basel), 2023 10.3390/cancers15225423
- J Biol Chem, 2023 S0021-9258(23)02118-X
- J Hepatocell Carcinoma, 2023 10:483-495
- RSC Adv, 2023 13(11):7656-7663
- Curr Oncol, 2023 30(11):9611-9626
- Anticancer Res, 2023 43(8):3411-3418
- Faculty of Life Sciences and Medicine, King’s College London, 2023
- Cancer Res Commun, 2023 Expression of PRMT5 is highly positively correlated to DNA damage repair (DDR) and DNA replication pathway genes in many types of cancer cells, includ
- Discov Oncol, 2023 14(1):139
- J Clin Invest, 2022 132(24)e151604
- Adv Sci (Weinh), 2022 9(28):e2201889
- Adv Sci (Weinh), 2022 e2201539
- Nat Protoc, 2022 10.1038/s41596-022-00740-4
- Acta Pharm Sin B, 2022 12(12):4407-4423
- Theranostics, 2022 12(11):5172-5188
- Clin Cancer Res, 2022 28(17):3874-3889
- J Exp Clin Cancer Res, 2022 41(1):312
- Clin Transl Med, 2022 12(10):e1088
- JCI Insight, 2022 7(22e158060)
- Elife, 2022 11e75231
- Stem Cell Res Ther, 2022 13(1):219
- Cell Death Discov, 2022 8(1):438
- Cell Death Discov, 2022 8(1):296
- Cell Death Discov, 2022 8(1):235
- iScience, 2022 25(10):105182
- Mol Ther Oncolytics, 2022 24:249-261
- Front Pharmacol, 2022 13:906043
- Front Pharmacol, 2022 13:1032975
- Oncotarget, 2022 13:92-104
- Cancers (Basel), 2022 14(5)1281
- J Pers Med, 2022 12(2)258
- Bioengineered, 2022 13(3):6126-6135
- Bioengineered, 2022 13(2):2076-2086
- Neoplasia, 2022 25:53-61
- J Biol Chem, 2022 S0021-9258(22)00034-5
- Front Oncol, 2022 12:869485
- Front Oncol, 2022 12:855674
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- J Gastroenterol Hepatol, 2022 10.1111/jgh.15775
- BMC Cancer, 2022 22(1):602
- Cancer Biol Ther, 2022 23(1):1-8
- Biochem Biophys Res Commun, 2022 607:117-123
- Fundam Clin Pharmacol, 2022 10.1111/fcp.12759
- Anticancer Agents Med Chem, 2022 22(5):851-863
- Exp Ther Med, 2022 23(4):282
- Pharmacol Res Perspect, 2022 10(5):e01016
- J Breast Cancer, 2022 25(6):500-512
- STAR Protoc, 2022 3(3):101559
- Nat Commun, 2021 12(1):4840
- Theranostics, 2021 11(9):4011-4029
- Cell Death Differ, 2021 10.1038/s41418-020-00733-4
- J Exp Clin Cancer Res, 2021 40(1):297
- MedComm (2020), 2021 2(3):467-480
- PLoS Biol, 2021 19(8):e3001364
- ACS Appl Mater Interfaces, 2021 13(41):48478-48491
- Int J Biol Sci, 2021 17(7):1808-1820
- Cell Death Dis, 2021 12(5):449
- Cell Death Dis, 2021 12(4):337
- Cell Death Dis, 2021 12(2):140
- Br J Cancer, 2021 10.1038/s41416-021-01639-9
- Cell Rep, 2021 34(10):108814
- Cell Chem Biol, 2021 S2451-9456(21)00306-8
- Cell Prolif, 2021 e13031
- Cell Mol Biol Lett, 2021 26(1):48
- Phytomedicine, 2021 85:153547
- Br J Pharmacol, 2021 178(11):2351-2369
- iScience, 2021 24(6):102664
- Mol Cancer Ther, 2021 molcanther.MCT-21-0474-A.2021
- Int J Mol Sci, 2021 22(23)12762
- Front Pharmacol, 2021 12:718675
- Front Pharmacol, 2021 12:689767
- Cancers (Basel), 2021 13(16)3927
- Cancers (Basel), 2021 13(11)2539
- Eur J Pharmacol, 2021 907:174222
- Neoplasia, 2021 23(3):304-325
- Front Oncol, 2021 11:711642
- Ann Transl Med, 2021 9(16):1317
- Molecules, 2021 26(16)4949
- Molecules, 2021 26(2)E334
- Environ Toxicol, 2021 10.1002/tox.23355
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Cancer Med, 2021 10.1002/cam4.4066
- Biosci Rep, 2021 BSR20200842
- J Cancer, 2021 12(24):7413-7421
- J Cancer, 2021 12(16):4862-4872
- J Cancer, 2021 12(6):1634-1643
- BMC Cancer, 2021 21(1):65
- BMC Cancer, 2021 21(1):923
- Mol Med Rep, 2021 23(3)172
- Exp Ther Med, 2021 22(4):1151
- Int J Radiat Biol, 2021 1-16
- J Pharmacokinet Pharmacodyn, 2021 10.1007/s10928-020-09732-x
- Sci Adv, 2021 7(36):eabh1684
- STAR Protoc, 2021 2(4):100880
- STAR Protoc, 2021 2(2):100574
- Journal of Cancer, 2021 12(16): 4862-4872
- Cell Rep Med, 2020 1(9):100160
- Acta Biomater, 2020 S1742-7061(20)30751-0
- Cancer Lett, 2020 473:74-89
- Oncogene, 2020 39(5):987-1003
- EMBO Rep, 2020 e49689
- Int J Cancer, 2020 10.1002/ijc.33393
- Microb Cell Fact, 2020 19(1):213
- mBio, 2020 11(3):e01190-20
- Oncogenesis, 2020 7;9(5):45
- Cells, 2020 9(11)E2438
- Cells, 2020 9(9)E2110
- Cancer Cell Int, 2020 19;20:58
- Front Pharmacol, 2020 11:666
- J Cell Physiol, 2020 10.1002/jcp.29580
- J Cell Physiol, 2020 10.1002/jcp.29464
- Am J Cancer Res, 2020 1;10(4):1255-1270 eCollection 2020
- Am J Cancer Res, 2020 10(2):403-423
- Cancers (Basel), 2020 12(9)E2580
- Cancers (Basel), 2020 12(6):E1590
- Int J Oncol, 2020 56(5):1140-1151
- Carcinogenesis, 2020 41(7):993-1004
- Cancer Res Treat, 2020 10.4143/crt.2020.585
- Sci Rep, 2020 10(1):13988
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Environ Toxicol Pharmacol, 2020 81:103513
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Onco Targets Ther, 2020 13:371-379
- J Cancer, 2020 11(18):5432-5439
- Cancer Manag Res, 2020 12:8465-8479
- Dig Dis Sci, 2020 65(4):1064-1073
- SLAS Discov, 2020 30:2472555220915827
- Exp Ther Med, 2020 20(2):1415-1422
- Anticancer Res, 2020 40(7):3659-3667
- Nat Commun, 2019 10(1):755
- Biomaterials, 2019 219:119400
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-2409
- Redox Biol, 2019 22:101131
- Cancer Res, 2019 79(8):2009-2020
- Cancer Lett, 2019 457:28-39
- J Nucl Med, 2019 10.2967/jnumed.118.224048
- Int J Biol Sci, 2019 15(2):312-324
- Cell Rep, 2019 27(11):3331-3344
- Cell Mol Gastroenterol Hepatol, 2019 7(1):161-184
- Cells, 2019 8(12)
- Cells, 2019 8(7)
- Biomolecules, 2019 9(8)E306
- Front Oncol, 2019 9:1406
- Molecules, 2019 24(6)
- Molecules, 2019 24(12)
- Mol Cell Biochem, 2019 461(1-2):151-158
- Cancer Med, 2019 10.1002/cam4.2764
- Biosci Rep, 2019 39(4)
- Med Oncol, 2019 36(12):97
- Mol Med Rep, 2019 19(2):1203-1209
- Biochem Biophys Res Commun, 2019 519(1):113-120
- Oncol Lett, 2019 18(6):5843-5852
- Nat Commun, 2018 13;9(1):2720
- Nucleic Acids Res, 2018 46(7):3284-3297
- J Exp Clin Cancer Res, 2018 37(1):151
- Biomed Pharmacother, 2018 104:204-210
- Cell Death Discov, 2018 4:116
- J Invest Dermatol, 2018 138(8):1716-1725
- Oncotarget, 2018 9(26):18239-18253
- Int J Oncol, 2018 53(5):2102-2110
- Int J Oncol, 2018 53(2):844-854
- Neoplasia, 2018 20(12):1236-1245
- Cell Physiol Biochem, 2018 46(4):1365-1380
- Neuroendocrinology, 2018 106(4):335-351
- Neuroendocrinology, 2018 106(1):58-73
- J Cell Biochem, 2018 119(11):9498-9512
- Cancer Manag Res, 2018 10:6205-6216
- Med Sci Monit, 2018 24:2735-2743
- Oncol Lett, 2018 15(5):6107-6114
- Oncol Lett, 2018 15(6):9385-9391
- Sci Adv, 2018 4(9):eaar4666
- Cancer Res, 2017 77(18):5039-5053
- Oncotarget, 2017 8(3):5349-5360
- Sci Rep, 2017 7(1):10921
- Cell Cycle, 2017 16(14):1376-1383
- Oncol Rep, 2017 38(4):2205-2210
- PLoS One, 2017 12(5):e0178375
- SLAS Discov, 2017 22(5):507-515
- Exp Ther Med, 2017 14(5):4263-4271
- Cell Death Dis, 2016 7(10):e2432
- Clin Transl Immunology, 2016 5(12):e119
- Am J Cancer Res, 2016 6(8):1681-94
- Mol Pharm, 2016 13(11):3724-3735
- Sci Rep, 2016 6:38306
- Sci Rep, 2016 6:29382
- PLoS One, 2016 11(6):e0158617
- Eur Rev Med Pharmacol Sci, 2016 20(9):1699-706
- Tissue Eng Part C Methods, 2016 22(7):621-35
- Mol Cell Biochem, 2014 10.1007/s11010-014-2253-6
- Biomed Res Int, 2014 2014:306718
- J Proteomics, 2014 113:326-36
- PLoS One, 2013 8(1):e54595
化学信息&溶解度
分子量 | 130.08 |
分子式 | C4H3FN2O2 |
CAS号 | 51-21-8 |
Smiles | C1=C(C(=O)NC(=O)N1)F |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 26 mg/mL ( 199.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 26 mg/mL ( 199.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 10 mg/mL Ethanol : Insoluble DMSO : 26 mg/mL ( 199.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 10 mg/mL Ethanol : Insoluble DMSO : 26 mg/mL ( 199.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:3.5mg/ml
(26.91mM)
操作示例:以 1 mL 工作液为例,取50μL70mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
Corn oil
浓度:0.65mg/ml
(5.00mM)
操作示例:以 1 mL 工作液为例,取50μL13mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。